As expected, a mixed sales performance, with faster momentum in molecular biology solutions contrasting with a slowdown in microbiology, immunoassays and industrial applications
Robust growth in contributive operating income before non-recurring items, to €253 million, or 17.1% of sales
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In today’s unprecedented health crisis, bioMérieux’s positioning as a specialist in infectious disease diagnostics takes on all of its meaning and allowed to rapidly provide high-performance solutions for diagnosing COVID-19. Despite the pandemic’s negative impact on certain product lines and taking into account health and economic conditions, bioMérieux is expected to deliver a remarkable performance this year. However, this performance is not projectable beyond 2020.”
